Brunella Zizolfi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brunella Zizolfi has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Attilio Di Spiezio Sardo
Department of Public Health, School of Medicine, University of Naples “Federico II”, 80131 Naples, Italy
14 shared publications Attilio Di Spiezio Sardo
7 shared publicationsAlessandra Gallo
Unit of Obstetrics and Gynecology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy
4 shared publicationsMaria Chiara De Angelis
Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples Federico II Faculty of Medicine, Naples, Italy
4 shared publicationsVirginia Foreste
Department of Public Health. University of Naples Federico II, Naples, Italy
4 shared publicationsCarmine Nappi
University of Naples “Federico II
3 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
Navigating the Obstacle: Hysteroscopic Management of Voluntary Termination of Pregnancy Behind a Giant Previa Isthmic Myoma
- 12 September 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
Open AccessNavigating the Obstacle: Hysteroscopic Management of Voluntary Termination of Pregnancy Behind a Giant Previa Isthmic Myoma
- Open Access
- 18 March 2026
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 18 (1) , 69-70
Hysteroscopic ablation of type 2 and type 3 fibroids using radiofrequency or microwave energy
Hysteroscopic ablation of type 2 and type 3 fibroids using radiofrequency or microwave energy - Facts, Views and Vision in ObGyn
- 18 March 2026
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 18 (1) , 69-70
Open AccessHysteroscopic ablation of type 2 and type 3 fibroids using radiofrequency or microwave energy
Hysteroscopic ablation of type 2 and type 3 fibroids using radiofrequency or microwave energy - Facts, Views and Vision in ObGyn
- 7 February 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (9) , 1239-1240
A Step-By-Step Description of the Hysteroscopic Injection of Platelet-Rich Plasma (PRP) Into the Endo-Myometrial Junction For Patients With Asherman’s Syndrome
- 7 February 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (9) , 1239-1240
A Step-By-Step Description of the Hysteroscopic Injection of Platelet-Rich Plasma (PRP) Into the Endo-Myometrial Junction For Patients With Asherman’s Syndrome
- Open Access
- 30 September 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (3) , 245-252
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids - Facts, Views and Vision in ObGyn
- 30 September 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (3) , 245-252
Open AccessSafety and efficacy of relugolix combination therapy in symptomatic uterine fibroids
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids - Facts, Views and Vision in ObGyn
- Open Access
- 23 June 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (2) , 121-129
The impact of virtual reality technology in the era of See & Treat hysteroscopy: a randomised controlled trial
The impact of virtual reality technology in the era of See & Treat hysteroscopy: a randomised controlled trial - Facts, Views and Vision in ObGyn
- 23 June 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (2) , 121-129
Open AccessThe impact of virtual reality technology in the era of See & Treat hysteroscopy: a randomised controlled trial
The impact of virtual reality technology in the era of See & Treat hysteroscopy: a randomised controlled trial - Facts, Views and Vision in ObGyn
- Open Access
- 27 May 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (2) , 204-207
A combined endoscopic and ultrasonographic approach to a complex U4a uterine anomaly
A combined endoscopic and ultrasonographic approach to a complex U4a uterine anomaly - Facts, Views and Vision in ObGyn
- 27 May 2025
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 17 (2) , 204-207
Open AccessA combined endoscopic and ultrasonographic approach to a complex U4a uterine anomaly
A combined endoscopic and ultrasonographic approach to a complex U4a uterine anomaly - Facts, Views and Vision in ObGyn
- Open Access
- 22 May 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (4) , 728-736
Quantitative ultrasound measurement of uterine contractility in septate uterus vs. normal uteri: a multicenter prospective study
- 22 May 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (4) , 728-736
Open AccessQuantitative ultrasound measurement of uterine contractility in septate uterus vs. normal uteri: a multicenter prospective study
- Open Access
Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases
Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs) are rare uterine mesenchymal neoplasms with uncertain biological potential. These tumors, which affect both premenopausal and postmenopausal women, usually have a benign clinical course. Nevertheless, local recurrences and distant metastases have been described. By analyzing 511 cases retrieved from individual reports and cases series, we provide here the most comprehensive overview of UTROSCT cases available in the literature, supplemented by two new cases of UTROSCTs. Case 1 was an asymptomatic 31-year-old woman who underwent a laparoscopic resection of a presumed leiomyoma. Case 2 was a 58-year-old postmenopausal woman with abnormal vaginal bleeding who underwent an outpatient hysteroscopic biopsy of a suspicious endometrial area. In both cases, immunohistochemical positivity for Calretinin and Inhibin was noted, typical for a sex cord differentiation. In both cases, total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed. In light of the available literature, no pathognomonic clinical or imaging finding can be attributed to UTROSCT. Patients usually present with abnormal uterine bleeding or pelvic discomfort, but 20% of them are asymptomatic. In most cases, a simple hysterectomy appears to be the appropriate treatment, but for women who wish to become pregnant, uterus-preserving approaches should be discussed after excluding risk factors. Age, tumor size, lymphovascular space invasion, nuclear atypia, and cervical involvement are not reliable prognostic factors in UTROSCT. The current research suggests that aggressive cases (with extrauterine spread or recurrence) can be identified based on a distinct genetic and immunohistochemical phenotype. For instance, UTROSCTs characterized by GREB1::NCOA1-3 fusions and PD-L1 molecule expression appear to be predisposed to more aggressive behaviors and recurrence, with GREB1::NCOA2 being the most common gene fusion in recurrent tumors. Hence, redefining the criteria for UTROSCTs may allow a better selection of women suitable for fertility-sparing treatments or requiring more aggressive treatments in the future.
Open AccessUterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases
Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs) are rare uterine mesenchymal neoplasms with uncertain biological potential. These tumors, which affect both premenopausal and postmenopausal women, usually have a benign clinical course. Nevertheless, local recurrences and distant metastases have been described. By analyzing 511 cases retrieved from individual reports and cases series, we provide here the most comprehensive overview of UTROSCT cases available in the literature, supplemented by two new cases of UTROSCTs. Case 1 was an asymptomatic 31-year-old woman who underwent a laparoscopic resection of a presumed leiomyoma. Case 2 was a 58-year-old postmenopausal woman with abnormal vaginal bleeding who underwent an outpatient hysteroscopic biopsy of a suspicious endometrial area. In both cases, immunohistochemical positivity for Calretinin and Inhibin was noted, typical for a sex cord differentiation. In both cases, total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed. In light of the available literature, no pathognomonic clinical or imaging finding can be attributed to UTROSCT. Patients usually present with abnormal uterine bleeding or pelvic discomfort, but 20% of them are asymptomatic. In most cases, a simple hysterectomy appears to be the appropriate treatment, but for women who wish to become pregnant, uterus-preserving approaches should be discussed after excluding risk factors. Age, tumor size, lymphovascular space invasion, nuclear atypia, and cervical involvement are not reliable prognostic factors in UTROSCT. The current research suggests that aggressive cases (with extrauterine spread or recurrence) can be identified based on a distinct genetic and immunohistochemical phenotype. For instance, UTROSCTs characterized by GREB1::NCOA1-3 fusions and PD-L1 molecule expression appear to be predisposed to more aggressive behaviors and recurrence, with GREB1::NCOA2 being the most common gene fusion in recurrent tumors. Hence, redefining the criteria for UTROSCTs may allow a better selection of women suitable for fertility-sparing treatments or requiring more aggressive treatments in the future.
- Open Access
- 1 December 2023
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 15 (4) , 339-349
Cavernous haemangioma and mid trimester pregnancy loss leading to severe haemorrhage and hysterectomy: a case report and review of literature
Background: Cavernous haemangiomas are benign vascular tumours that are known to occasionally involve the female genital tract, including the uterus. They are often underdiagnosed during pregnancy, although they can also lead to severe postpartum or antepartum haemorrhage. Objectives: Describe our case of an uncommon second-trimester pregnancy loss in a woman with a diffuse cavernous haemangioma of the uterus and cervix and review the wider literature. Methods: The review was conducted using MEDLINE, Scopus and PubMed electronic databases from beginning of the database to May 2023, using the following keywords: arteriovenous malformation; cavernous haemangioma/hemangioma; uterine neoplasms; pregnancy complications; abnormal vaginal bleeding. Main outcome measures: Description of the characteristics of cavernous haemangioma during pregnancy as well as diagnostic criteria and treatment options. Results: Twenty publications were included in the review, which included English-language case reports over a period from 1959 to 2022. No pathognomonic symptoms for cavernous haemangioma of the uterus in a pregnant woman were noted. Complications including massive secondary postpartum haemorrhage, haemoperitoneum, and severe thrombocytopenia with anaemia after delivery were reported. Conclusions: Diagnosis and management during pregnancy can be challenging and requires considerable attention, with a multidisciplinary approach including gynaecologists, radiologists, and pathologists to avoid major complications. What is new? An additional case of diffuse cavernous haemangioma of the uterus and cervix is described, that adds to the little existing literature.
- 1 December 2023
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 15 (4) , 339-349
Open AccessCavernous haemangioma and mid trimester pregnancy loss leading to severe haemorrhage and hysterectomy: a case report and review of literature
Background: Cavernous haemangiomas are benign vascular tumours that are known to occasionally involve the female genital tract, including the uterus. They are often underdiagnosed during pregnancy, although they can also lead to severe postpartum or antepartum haemorrhage. Objectives: Describe our case of an uncommon second-trimester pregnancy loss in a woman with a diffuse cavernous haemangioma of the uterus and cervix and review the wider literature. Methods: The review was conducted using MEDLINE, Scopus and PubMed electronic databases from beginning of the database to May 2023, using the following keywords: arteriovenous malformation; cavernous haemangioma/hemangioma; uterine neoplasms; pregnancy complications; abnormal vaginal bleeding. Main outcome measures: Description of the characteristics of cavernous haemangioma during pregnancy as well as diagnostic criteria and treatment options. Results: Twenty publications were included in the review, which included English-language case reports over a period from 1959 to 2022. No pathognomonic symptoms for cavernous haemangioma of the uterus in a pregnant woman were noted. Complications including massive secondary postpartum haemorrhage, haemoperitoneum, and severe thrombocytopenia with anaemia after delivery were reported. Conclusions: Diagnosis and management during pregnancy can be challenging and requires considerable attention, with a multidisciplinary approach including gynaecologists, radiologists, and pathologists to avoid major complications. What is new? An additional case of diffuse cavernous haemangioma of the uterus and cervix is described, that adds to the little existing literature.